Robert Marcus
Stock Analyst at JP Morgan
(1.51)
# 3,407
Out of 5,182 analysts
24
Total ratings
55.56%
Success rate
-0.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $175 | $155.52 | +12.53% | 11 | Feb 10, 2026 | |
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $332.42 | +11.30% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $11.03 | +579.96% | 2 | Dec 17, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $121.00 | -58.68% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $116.11 | -87.08% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $29.37 | +94.08% | 2 | Jul 29, 2020 |
Becton, Dickinson and Company
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $175
Current: $155.52
Upside: +12.53%
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $332.42
Upside: +11.30%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $11.03
Upside: +579.96%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $121.00
Upside: -58.68%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $116.11
Upside: -87.08%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $29.37
Upside: +94.08%